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Introduction
Malignant peripheral nerve sheath tumors (MPNSTs) are highly 
aggressive sarcomas with a strong metastatic potential, usually 
to the lung (1). MPNST patients are largely refractory to current 
treatments that include radical surgical resection and/or radia-
tion and chemotherapy, and have very poor 5-year survival rates 
ranging between 15% and 50% (1). Half of MPNST cases arise 
in the context of neurofibromatosis type 1 syndrome (NF1), and 
these tumors are a leading cause of death in NF1 patients. In 
NF1, loss of the NF1 tumor suppressor gene that encodes the Ras 
GTPase-activating protein neurofibromin leads to the develop-
ment of benign neurofibromas that are located on the skin (cuta-
neous neurofibromas) or can be deep-seated in large peripheral 
nerves (plexiform neurofibromas). Plexiform neurofibromas can 
transform into MPNSTs, which can also occur spontaneously 
(sporadic MPNSTs) or after radiotherapy. There is general accep-
tance that cells of the Schwann cell lineage are the crucial neo-
plastic cells in MPNSTs (1, 2).
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression 
programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/
ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive 
sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a 
multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition 
of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. 
Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential 
oncogenic pathways in MPNST cells, including the Wnt/β-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge 
on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and 
dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
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proliferation. Targeting dysregulated gene expression programs 
in cancers has emerged as a promising therapeutic strategy, and 
there is an intense focus on identifying the key molecular regula-
tors that govern these programs (9, 10). In particular, RNA-binding 
proteins (RBPs) are increasingly recognized as attractive targets 
because of their ability to regulate the type and abundance of hun-
dreds of transcripts by modulating every aspect of their post-tran-
scriptional life — splicing, transport, localization, translation, sta-
bilization, and decay. Furthermore, each RBP can bind to multiple 
overlapping groups of functionally related RNAs, forming “RNA 
regulons” that control many biological functions (11).
We have previously shown that the ubiquitously expressed RBP 
HuR/ELAVL1 was highly expressed in immature Schwann cells, 
a stage of development characterized by a peak in Schwann cell 
proliferation and apoptosis. We found that HuR was bound to and 
regulated several key mRNAs, coordinately regulating them at the 
post-transcriptional level (12). Subsequently, as immature Schwann 
cells differentiated, we found that they lost expression of HuR, and 
the production of HuR targets encoding proliferation and apopto-
sis proteins was downregulated. Notably, many of the HuR targets 
in immature Schwann cells become re-expressed in MPNSTs, and 
the encoded proteins play key roles in tumor growth, as shown for 
SOX9 (8) and BRD4 (13). HuR is frequently upregulated in different 
A number of mutations that drive MPNST pathogenesis have 
been identified, with a surprising degree of overlap in NF1-associ-
ated and sporadic forms. These include molecular variants of the 
NF1 tumor suppressor gene that are present in all NF1 patients, 
and in a majority of sporadic and radiation-induced MPNSTs (2, 
3). Other ancillary, yet essential, cancer-driving genetic aberra-
tions include loss of the genes CDKN2A, TP53, RB, or PTEN, or 
the genes encoding the PRC2 components SUZ12 or EED, and 
amplification of PDGFRA, EGFR, or MET (4, 5). In addition, 
recent studies have shown that activation of multiple signaling 
pathways, including the PI3K/AKT/mTOR, RAS/RAF-MEK-
ERK, Wnt/β-catenin, and HIPPO-YAP/TAZ pathways, and other 
less ubiquitous molecular alterations involving aurora kinases 
and transcription factors (TFs) such as SOX9, also contribute to 
MPNST pathogenesis (1, 3, 6).
Gene dysregulation is a hallmark of cancer cells. Genetic 
alterations in cancer cells invariably lead to a global remodeling 
of their transcriptome, allowing them to acquire advanced func-
tional capabilities for survival, proliferation, and dissemination. 
MPNSTs have a unique transcriptomic signature that is clearly dis-
tinct from normal or even neurofibroma-derived primary Schwann 
cells or tumors (7, 8), and strongly associated with key Schwann 
cell developmental programs, including control of survival and 
Figure 1. HuR is upregulated in human MPNSTs. (A and B) HuR mRNA levels in nerves, neurofibromas, and MPNSTs from patients (A) and mouse models 
(B) from the Jessen cohort (GSE41747) (7). (C) Representative immunohistochemistry micrographs of endogenous HuR protein levels (brown) in a tissue 
microarray panel of human nerves (n = 7), benign neurofibromas (n = 76), and MPNSTs (n = 109) (15). Score 0, low HuR staining; 1, intermediate staining; 2, 
high HuR staining. Scale bar: 50 μm. (D–G) Western blot and quantitative reverse transcriptase PCR (RT-qPCR) analysis of HuR levels in a panel of human 
nerves (n = 5), benign neurofibromas (n = 12), and MPNSTs (n = 15) obtained from Stanmore Musculoskeletal Biobank. (D) Representative immunoblots 
showing total and cytoplasmic HuR levels in a selection of samples. (E and F) Graphs representing densitometry analysis of total HuR protein levels, 
corrected for Ponceau red signals (E), and cytoplasmic HuR protein levels, corrected for Ponceau red signals (F). (G) HuR mRNA levels as measured by RT- 
qPCR analysis. Data are presented as mean ± SEM (A and B) or median with interquartile range (E–G); 1-way ANOVA with Tukey’s multiple-comparisons 
test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The number of samples (n) per group is indicated.
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from the Stanmore Musculoskeletal Biobank (United Kingdom). 
We confirmed that total HuR protein levels were significantly ele-
vated in the MPNST samples (Figure 1, D and E). We also exam-
ined cytoplasmic HuR levels, since HuR export from the nucleus 
to the cytoplasm is linked to its function as a post-transcriptional 
regulator of target mRNAs (16). As shown (Figure 1, D and F), cyto-
plasmic HuR levels were higher in MPNST samples. HuR mRNA 
levels were also higher in these samples (Figure 1G).
We did not find significant differences in the abundance of 
HuR mRNA or protein when comparing dermal neurofibromas 
and plexiform neurofibromas from our frozen cancer panel (Sup-
plemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/JCI130379DS1; see complete 
unedited blots in the supplemental material), nor were there 
differences in HuR mRNA levels in publicly available data sets 
(Supplemental Figure 1, B and C). Notably, we also did not find 
significant differences in the levels of HuR mRNA or protein when 
comparing NF1-derived and sporadic MPNSTs (Supplemental 
Figure 1, D and E).
The high abundance and cytoplasmic localization of HuR 
point to a potentially important role in both sporadic and NF1- 
derived MPNSTs.
cancer types (14), leading us to hypothesize that HuR could become 
re-expressed in MPNSTs, where it would have a key role in driving 
the dysregulated transcriptomic programs. Here, we present evi-
dence that HuR is potently tumorigenic in MPNSTs and that sup-
pressing HuR expression reduces tumor growth and metastasis. We 
propose that the malignant influence of HuR is linked to enhancing 
multiple key oncogenic programs operating in MPNST cells.
Results
HuR is upregulated in human MPNSTs. To explore the potential role 
of HuR in Schwann cell cancers, we searched a publicly available 
expression data set (Gene Expression Omnibus [GEO] GSE41747) 
(7) and found that HuR/ELAVL1 mRNA levels were significantly 
upregulated in MPNSTs, both in patients and in mouse samples 
(Figure 1, A and B). Next, we analyzed HuR protein abundance by 
immunohistochemistry in a human tissue microarray panel com-
prising normal nerves (n = 7), benign neurofibromas (n = 76), and 
MPNSTs (n = 109) (15) and, similarly, found a strong upregulation 
of HuR protein expression in MPNSTs (Figure 1C). Finally, we val-
idated these results by examining HuR protein and mRNA expres-
sion in an independent cohort of frozen human normal nerves 
(n = 5), neurofibromas (n = 12), and MPNSTs (n = 15), obtained 
Figure 2. HuR is bound to key targets in human MPNSTs. (A) Volcano plots show enrichment of transcripts most significantly bound to HuR compared 
with control IgG in neurofibromas (left) (n = 8) and MPNSTs (right) (n = 12) obtained from Stanmore Musculoskeletal Biobank. Red or blue dots, fold change 
>1.5; adjusted P value < 0.05. Venn diagram shows overlap between putative HuR mRNA targets from neurofibromas and MPNSTs. (B) GSEA analysis of 
putative HuR mRNA targets in MPNSTs for MSigDB hallmarks. The top 20 gene sets (FDR iQ values < 0.1) are plotted relative to normalized enrichment 
score (NES). Circles denote the number of enriched genes in each category. (C and D) GSEA plots of HuR IP and control IgG IP for key cancer traits (C) and 
oncogenic pathways (D) in MPNSTs.
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to 71 and 276 mRNAs in neurofibroma and MPNST samples, respec-
tively (Figure 2A and Supplemental Tables 1 and 2). The large major-
ity of neurofibroma targets (60 of 71; 85%) were also associated with 
HuR in the MPNST samples, whereas 216 HuR-bound transcripts 
were exclusively expressed in MPNST samples (Figure 2A), in line 
with the high HuR expression in MPNST samples, and supporting a 
role for HuR in malignant Schwann cell tumors.
To identify molecular pathways associated with HuR-bound 
transcripts in MPNSTs, we performed gene set enrichment analysis 
(GSEA) using Molecular Signatures Database (MSigDB) hallmarks 
(20). GSEA revealed significant enrichment of signatures associ-
ated with oncogenic traits including cell cycle progression, epithe-
lial-mesenchymal transition, and angiogenesis (21), as well as sig-
natures for the key oncogenic TFs MYC and E2F (refs. 22, 23, and 
Figure 2B). In addition, key signaling pathways in MPNSTs, includ-
ing the Wnt/β-catenin, PI3K/AKT/mTOR, and RAS pathways (1, 2), 
were also enriched (Figure 2, B–D, and Supplemental Table 3).
Together, these data point to a potentially important biologi-
cal function of HuR in MPNSTs, possibly regulating key signaling 
pathways that control oncogenic traits in these malignant tumors.
RIP-Chip identifies HuR mRNA targets associated with key 
cancer traits. To examine the biological significance of the high 
HuR levels in MPNSTs, we analyzed HuR-associated mRNAs on 
a genome-wide scale by ribonucleoprotein immunoprecipitation 
(RIP) under conditions that preserve endogenous RNA-protein 
interactions, followed by microarray detection of bound mRNAs 
(RIP-Chip) (17, 18). Notably, RIP preferentially enriches for 
the stably bound subsets of putative mRNA targets rather than 
transient targets that might be detected by ribonucleoprotein 
cross-linking. This favors the identification of targets forming 
part of functional complexes that lead to mRNA target stabiliza-
tion and increased translation (19).
RIP analysis was performed using an anti-HuR antibody or con-
trol anti-IgG antibody and cytoplasmic extracts from human neurofi-
broma (n = 8) and MPNST (n = 12) samples from the aforementioned 
frozen cancer panel, and the isolated RNA was identified by microar-
ray analysis (Supplemental Figure 2, A and B). Background mRNAs 
identified in side-by-side control immunoprecipitation reactions 
using mouse anti-IgG antibody were subtracted to identify bona fide 
HuR-interacting mRNAs. We found that HuR was specifically bound 
Figure 3. HuR promotes MPNST cell growth in vivo. (A and B) Constitutive HuR silencing prevents tumor formation in vivo. (A) Schematic representation 
of xenotransplantation experiments. (B) Representative pictures of tumors from nude mice injected with shCtrl or shHuR#1 STS-26T MPNST cells 5 weeks 
after transplant (n = 5) for each condition. Scale bar: 5 mm. (C–F) Inducible HuR silencing promotes tumor regression in vivo. (C) Schematic representation 
of xenotransplantation experiments using inducible HuR-silencing strategy. (D) Representative pictures of tumors from nude mice injected with sh iCtrl 
or sh iHuR STS-26T MPNST cells on left and right flank, respectively, at 20 days after injection (day 20) and 10 days later (day 30), with (+ Dox) or without 
doxycycline diet (– Dox). (E) Waterfall plot showing change in tumor volume (represented as log2 fold change) of individual tumors formed at 20 days after 
transplant and after 10 days with or without doxycycline treatment for each of 4 groups of mice. sh iCtrl (–Dox) n = 7; sh iCtrl (+Dox) n = 7; sh iHuR (–Dox) 
n = 7; sh iHuR (+Dox) n = 7. (F) Graph showing weight of excised tumors for the 4 groups of mice. Each data point represents 1 mouse; 1-way ANOVA with 
Tukey’s multiple-comparisons test. **P < 0.01; ***P < 0.001; ****P < 0.0001.
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although they differ in proliferation rates and in expression of cell 
cycle proteins (24). Both constitutively expressed shRNAs reduced 
HuR levels efficiently, and suppressed cell growth, as shown by 
measurement of ATP levels and by direct cell counts in all 4 cell 
lines (Supplemental Figure 3, D–F). Furthermore, HuR silencing 
significantly reduced the clonogenic and anchorage-independent 
growth capacity of all 4 cell lines (Supplemental Figure 4, A–C).
Since the in vitro consequences of HuR perturbation were 
shared by all MPNST cell lines, we selected as representative 
STS-26T for in vivo validation. STS-26T cells in which HuR lev-
els were normal or reduced by silencing were implanted subcuta-
neously in immunodeficient mice. Subsequent analysis revealed 
that whereas control cells efficiently formed tumors (5/5), tumor 
formation was completely abolished in HuR-silenced cells (0/5) 
(Figure 3, A and B).
Next, we examined the effects of HuR depletion on the 
growth of already established tumors. To this end, we used a dox-
ycycline-inducible lentiviral shRNA system targeting HuR. STS-
26T cells expressing pTRIPZ-shControl (sh iCtrl) or pTRIPZ-
HuR promotes MPNST cell growth in vitro and in vivo. To charac-
terize the functional importance of HuR, we first evaluated its abun-
dance in established MPNST cell lines. Using a publicly available 
expression data set (GEO GSE14038) (8), we found that HuR mRNA 
levels were significantly upregulated in MPNST cell lines compared 
with neurofibroma-derived Schwann cells (Supplemental Fig-
ure 3A). Furthermore, higher HuR mRNA and protein levels were 
observed in 4 commonly used MPNST cell lines — ST88-14, 90-8, 
S462, and STS-26T — compared with freshly isolated Schwann cells 
derived from human nerves (Supplemental Figure 3, B and C).
We then silenced HuR in these 4 MPNST cell lines by lentiviral 
delivery of 2 distinct HuR-specific shRNAs and examined cellu-
lar growth. Three of the cell lines (ST88-14, 90-8, and S462) were 
derived from NF1 patients with confirmed loss of heterozygosity 
at the NF1 locus for all 3 cell lines; the 90-8 cell line additional-
ly showed a known microdeletion of NF1, whereas the sporadic 
MPNST line STS-26T had no mutations detected in the 60 exons 
of the NF1 gene. These MPNST cell lines share a common gene 
expression profile distinct from that of normal Schwann cells, 
Figure 4. HuR promotes MPNST metastasis in vivo. (A–C) Constitutive HuR silencing prevents lung metastasis of STS-26T MPNST cells. (A) Schematic 
representation of lung metastasis experiments. shCtrl (n = 6) or shHuR#1-expressing (n = 7) STS-26T MPNST cells were injected in the tail vein of nude 
mice, and lung architecture analyzed by H&E staining 4 weeks later. Representative pictures of lung histology are shown. Scale bar: 2 mm. (B and C) 
Number of lung metastases (B) and lung metastatic area, expressed as a percentage of total lung area (C), were quantified by H&E histology. (D–F) Induc-
ible HuR silencing prevents growth of established lung metastatic nodules. (D) Schematic representation of experiments. sh iCtrl or sh iHuR–expressing 
STS-26T MPNST cells were injected in the tail vein of nude mice. A group of mice (n = 3 for each condition) was sacrificed at 2 weeks (W2) to analyze basal 
formation of lung metastases, and the rest fed with normal diet (–Dox) or doxycycline diet to induce expression of shRNAs (+Dox) for a further 4 weeks 
before analysis of lung histology by H&E staining. Representative pictures of lung histology for the following groups are shown: sh iCtrl with normal diet 
(sh iCtrl; –Dox) n = 5; sh iCtrl with doxycycline diet (sh iCtrl; +Dox) n = 5, sh iHuR with normal diet (sh iHuR; –Dox) n = 5, sh iHuR with doxycycline diet (sh 
iHuR; +Dox) n = 5. Scale bar: 2 mm. (E and F) Number of lung metastases (E) and lung metastatic area, expressed as a percentage of total lung area (F), 
were quantified. Each data point represents 1 mouse. Data are presented as mean ± SEM; 2-tailed unpaired Mann-Whitney U test (B and C); 1-way ANOVA 
with Holm-Šidák multiple-comparisons test (E and F). *P < 0.05; **P < 0.01.
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shHuR (sh iHuR) were injected subcutaneously in the left and 
right flanks of immunodeficient mice, respectively, and tumors 
were allowed to form for about 20 days until they were palpable 
(~100 mm3 average). Mice were randomly assigned to standard 
chow diet or doxycycline diet for a period of 10 days, whereupon 
mice were sacrificed and tumors extracted (Figure 3C). Remark-
ably, induction of HuR shRNA by doxycycline treatment severely 
blunted tumor growth, and even led to visible tumor regression 
(Figure 3D). Tumor regression was observed in all mice following 
HuR depletion, and on average tumors shrank by 40% (Figure 3E) 
and weighed significantly less than control tumors (Figure 3F). 
HuR-depleted cells formed smaller tumors, and the efficiency of 
Figure 5. Pharmacological inhibition of HuR blocks MPNST cell growth and metastasis in vitro and in vivo. (A and B) Pharmacological inhibition of HuR 
activity leads to a reduction in cell growth in MPNST cell lines ST88-14 and STS-26T, as determined by ATP luminescence, counts of cell numbers, clonogenic 
assays (foci), and anchorage-independent growth using soft agar assays. Graphs represent absorbance of crystal violet–stained colonies for clonogenic assays 
and number of colonies in soft agar assays. Data are normalized to DMSO-treated and are presented as mean ± SEM. Each data point represents 1 independent 
experiment; 1-way ANOVA with Tukey’s multiple-comparisons test. (C–E) Pharmacological inhibition of HuR activity by MS-444 promotes tumor regression in 
vivo. (C) Pictures of tumors from nude mice injected with STS-26T MPNST cells after vehicle or MS-444 treatment. Scale bar: 10 mm. (D) Graph showing weight 
of excised tumors for both groups of mice. (E) Waterfall plot showing change in tumor volume (represented as log2 fold change) of individual tumors formed at 
20 days after transplant, and after 10 days with pharmacological inhibition. Each data point represents 1 mouse. Data are presented as mean ± SEM; 2-tailed 
unpaired Mann-Whitney U test. (F–H) Pharmacological inhibition of HuR activity by MS-444 prevents growth of established lung metastatic nodules in vivo. 
(F) Representative pictures of lung histology from nude mice injected with STS-26T MPNST cells after vehicle or MS-444 treatment. Scale bar: 5 mm. (G and H) 
Number of lung metastases (G) and lung metastatic area, expressed as a percentage of total lung area (H), were quantified. Each data point represents 1 mouse. 
Data are presented as mean ± SEM; 2-tailed unpaired Mann-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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HuR silencing was confirmed in those tumors by Western blot-
ting analysis (Supplemental Figure 5, A and B). Notably, tumors 
arising from sh iHuR cells without doxycycline treatment were 
indistinguishable in all parameters from tumors arising from sh 
iCtrl cells with or without doxycycline treatment, supporting the 
efficiency and specificity of the inducible system used.
We also documented a marked reduction in the proliferation 
marker Ki67 and a rise in an apoptotic marker, active caspase-3, 
in HuR-depleted tumors (Supplemental Figure 5C). We validat-
ed these results in the panel of cultured MPNST cell lines, where, 
similarly, genetic depletion of HuR in the 4 cell lines potently 
reduced cell proliferation as measured by (a) cell cycle analysis 
by flow cytometry, which showed a general increase in the per-
centage of cells in the G1 phase and a decrease in cells in the S and 
G2/M phases, consistent with a G1 cell cycle arrest, and (b) BrdU 
incorporation (Supplemental Figure 6, A and B). We also found 
a marked increase in senescence after HuR silencing in all 4 cell 
lines (Supplemental Figure 6C). Detection of annexin V by flow 
cytometry indicated a trend toward increased apoptosis in all 4 
cell lines after HuR knockdown when cells were cultured under 
basal, growth-promoting conditions (10% serum). Exposure to 
cellular stress, such as culture of cells under growth-limiting 
conditions (2% serum) (13), exaggerated this effect and led to a 
marked increase in apoptotic and necrotic cell death after HuR 
depletion (Supplemental Figure 6D).
Together, these data indicate that HuR plays an important 
functional role in MPNST cell biology by controlling key features 
such as survival, proliferation, and replicative immortality.
HuR promotes MPNST metastasis in vivo. MPNSTs have a high 
metastatic potential, and up to 50% of patients develop metastat-
ic disease, usually to the lung, further worsening 5-year survival 
rates of patients (1, 25). Yet, metastasis is one of the least under-
stood aspects of MPNSTs. Given the profound antitumor effects 
of HuR in MPNST cells, and the identification of epithelial-mes-
enchymal transition signature as one of the top enriched catego-
ries of HuR targets from GSEA analysis (Figure 2, B and C), we 
decided to examine whether HuR could be important for MPNST 
metastasis, using a surrogate model of lung metastasis. Briefly, 
this model measures the ability of cells injected in the lateral tail 
vein of immunodeficient mice to survive in circulation, arrest at a 
distant organ, extravasate, adapt to growth in the foreign micro-
environments of a distant tissue, and grow into metastatic lesions, 
recapitulating many of the essential late steps in metastasis (26).
We silenced HuR constitutively in STS-26T cells, an MPNST 
cell line that exhibits metastatic tropism to the lung (27), injected 
them in the tail vein, and examined metastatic colonization of the 
lung 4 weeks later by histology (Figure 4A). Remarkably, very few 
metastatic lesions were observed in HuR-depleted cells in contrast 
to control cells, which formed numerous and large metastatic foci 
(Figure 4, B and C). Next, we used our inducible lentiviral silencing 
Figure 6. RNA-Seq reveals that HuR controls key oncogenic pathways in MPNSTs. (A) Heatmap representation of differentially expressed genes between 
shCtrl (n = 3) or shHuR#1-expressing (n = 3) ST88-14 MPNST cells (fold change >2; adjusted P value < 0.05). (B) Volcano plot of transcriptome profiles 
between shCtrl (n = 3) and shHuR#1-expressing (n = 3) ST88-14 MPNST cells. Red and blue dots represent genes significantly upregulated and downreg-
ulated, respectively, in shHuR#1-expressing cells (fold change >2; adjusted P value < 0.05). (C) GSEA analysis of shCtrl and shHuR#1-expressing ST88-14 
MPNST cells for MSigDB oncogenic signatures. Gene sets with FDR Q values less than 0.25 are plotted relative to normalized enrichment score (NES). 
Categories with negative (left) and positive (right) NES are down- or upregulated, respectively, in shCtrl cells. Circles denote the number of enriched genes 
in each category, and colors represent FDR Q values as indicated.
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as shown by measurement of ATP levels and by direct cell counts, 
and increased the clonogenic and anchorage-independent growth 
capacity (Supplemental Figure 7B). However, no major effect 
was observed on tumor formation in vivo using mouse xenograft 
models (Supplemental Figure 7, C and D). We also did not observe 
any major effect on tumor formation after ectopic expression of 
HuR in immortalized plexiform neurofibroma–derived human 
Schwann cells (ipNF SC). These data suggest that while HuR over-
expression promotes proliferation in Schwann cells in culture, it is 
not sufficient to induce Schwann cell–derived tumors in mice.
Similarly, we examined metastatic properties using tail vein 
injections of control or HuR-overexpressing normal and plexi-
form neurofibroma-derived human Schwann cell lines. We did 
not find any metastatic nodules in the controls of either cell line. 
Unexpectedly, we found the presence of small micrometastases in 
HuR-overexpressing normal Schwann cell lines (1 of 4) and plexi-
form human Schwann cell lines (3 of 4) (Supplemental Figure 7E), 
although these were far fewer and smaller than after injection of 
STS-26T MPNST cell line (Figure 4).
Taken together, our results showed that HuR overexpression in 
normal or plexiform neurofibroma Schwann cells was not sufficient 
to trigger oncogenic transformation but modestly increased their 
metastatic capacity.
Pharmacological inhibition of HuR reduces MPNST growth and 
metastasis. Our results demonstrate that elevated HuR levels in 
MPNST cells are required for cell growth and metastasis. We next 
ascertained whether the inhibition of HuR could be exploited as a 
therapeutic strategy using small-molecule HuR inhibitors.
system to examine the effect of HuR silencing on the colonization 
step of the metastatic process, i.e., the survival of the cells in these 
foreign microenvironments during the metastatic process, and the 
reactivation of their proliferation programs to form overt metastat-
ic lesions. We injected STS-26T cells expressing pTRIPZ-shControl 
(sh iCtrl) or pTRIPZ-shHuR (sh iHuR) in the tail vein, and allowed 
them to begin to form metastases for 2 weeks. Mice were ran-
domly assigned to standard chow or doxycycline-containing diet 
for 4 weeks, whereupon mice were sacrificed and lungs extracted 
for histological analysis (Figure 4D). Induction of HuR shRNA by 
doxy cycline treatment blocked the conversion of these micro-
metastases into the macroscopic neoplastic growth seen in the 
control cells with or without doxycycline treatment and in sh iHuR 
cells without doxycycline treatment (Figure 4, D–F).
Together, these data support a key role for HuR in MPNST 
metastasis, potentially controlling key aspects of the metastatic 
process, from the survival of the cells in the bloodstream to their 
colonization and proliferation within distant organs.
HuR overexpression in Schwann cells is not sufficient to trigger 
oncogenic transformation or dissemination. Since HuR is expressed 
at notably higher levels in MPNST compared with Schwann cells 
(Figure 1 and Supplemental Figure 3, A–C), we next examined 
whether elevating HuR levels in human Schwann cells was suffi-
cient to elicit cell transformation and dissemination.
We ectopically expressed HA-tagged HuR using a doxycy-
cline-inducible lentiviral system (28) in immortalized normal 
human Schwann cells (iHSCλ2) (Supplemental Figure 7A), and 
found that this led to a small but significant increase in cell growth, 
Figure 7. HuR regulates the YAP/TAZ pathway in MPNSTs. (A and B) GSEA plots showing enrichment of YAP-conserved signature from Figure 6C (A) and 
YAP-activated signature set (36) (B) in shCtrl-infected compared with shHuR#1-infected ST88-14 MPNST cells. (C) RIP-qPCR analysis showing binding of 
HuR to YAP1, TEAD1, and TEAD2 in 4 MPNST cell lines (ST88-14, 90-8, S462, and STS-26T). Data are normalized to control IgG IPs and are presented as 
mean ± SEM, 2-tailed unpaired Student’s t test; n = 4 MPNST cell lines. (D) Representative Western blots showing a general downregulation of key YAP/
TAZ pathway components after HuR silencing in ST88-14 MPNST cells. Technical duplicates are shown, and similar results were obtained in at least 3 inde-
pendent experiments. (E) RT-qPCR analysis showing downregulation of YAP/TAZ pathway effector genes (6) after HuR silencing in ST88-14 MPNST cells. 
Data are normalized to shCtrl cells and are presented as mean ± SEM. Each data point represents 1 independent experiment; 1-way ANOVA with Tukey’s 
multiple-comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001.
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HuR regulates key oncogenic transcriptional programs. Next, we 
sought to define the mechanisms by which HuR exerts such profound 
effects on MPNST cells. We silenced HuR expression using lentiviral 
vectors expressing constitutive shRNA directed at HuR in the ST88-
14 cell line, and performed RNA-Seq profiling. We identified distinct 
transcriptomic profiles between the control and HuR-depleted cells 
(Figure 6A), and differential expression analysis revealed that a nota-
ble proportion of the transcriptome in MPNST cells changed signifi-
cantly. There were similar numbers of significantly upregulated and 
downregulated transcripts exhibiting more than 2-fold changes (1563 
and 1627, respectively) (Figure 6B and Supplemental Table 4).
GSEA analysis revealed an inhibition of several tumorigen-
ic pathways in MPNST cells by HuR silencing, including the YAP/
TAZ, Wnt/β-catenin, PI3K/AKT/mTOR, and RAS pathways, in 
addition to signatures for the key oncogenic TFs MYC and E2F (Fig-
ure 6C and Supplemental Tables 5 and 6). There was also significant 
overlap between the signature sets we identified by this RNA-Seq 
analysis and the RIP-Chip analysis for putative HuR mRNA tar-
gets (Figure 2B). These results strongly suggested that HuR could 
be affecting MPNST cells by directly regulating these pathways, 
several of which have already been established to play key roles in 
MPNST tumorigenesis (6, 7, 13, 32–34). We thus set out to examine 
the importance of HuR for these pathways.
We first focused on the YAP/TAZ pathway. In an elegant 
study, it was recently shown that human MPNSTs exhibit ele-
Pharmacological inhibition of HuR with MS-444, which 
inhibits HuR homodimerization to prevent the binding of 3′-UTR 
AU-rich elements (29); pyrvinium pamoate, an FDA-approved 
anthelmintic drug that blocks HuR nucleocytoplasmic translo-
cation (30); and tanshinone mimic 6N (TM-6N), which inhibits 
HuR-RNA complex formation (31), each strongly reduced MPNST 
cell growth in culture in ST88-14 and STS-26T cells (Figure 5, A 
and B), similarly to what we found through the genetic inhibition 
of HuR (Supplemental Figures 3 and 4).
Importantly, i.p. injection with MS-444 (25 mg/kg body 
weight; treatment every 48 hours for 10 days) of nude mice bear-
ing already established tumors (formed 20 days after xenograft 
transplant of STS-26T cells in flanks) severely blunted tumor 
growth, and even led to tumor regression in some cases. In addi-
tion, MS-444–treated tumors weighed significantly less than 
control tumors (Figure 5, C–E). Remarkably, MS-444 treatment 
of nude mice (i.p. injection every 48 hours for 2 weeks; 25 mg/kg 
body weight) with established micrometastases that had formed 
for 2 weeks after i.v. injection of STS-26T cells also reduced the 
conversion of these micrometastases into the macroscopic neo-
plastic growth, and smaller metastatic areas were measured in 
MS-444–treated mice than in vehicle-treated mice (Figure 5, F–H).
Our results show that pharmacological inhibition of HuR 
reduces MPNST growth and metastasis, thus highlighting the rel-
evance of HuR as a potential therapeutic target for MPNSTs.
Figure 8. HuR regulates the RB/E2F pathway in MPNSTs. (A and B) GSEA plots showing enrichment of functionally defined RB (A) and E2F1 (B) signature 
set in shCtrl-infected compared with shHuR#1-infected ST88-14 MPNST cells from Figure 6C. (C) Cartoon depicting regulatory components of the RB/E2F 
pathway in cell cycle regulation. By interacting with CDKs, cyclins form complexes (cyclin D with CDK4/6 and cyclin E with CDK2) that phosphorylate RB1 (phos-
phorylated RB1 is inactive). When RB1 is phosphorylated, E2F is released and can transcriptionally activate its target genes, enabling the G1/S transition of cell 
cycle. Cyclins can be regulated at the transcription level by the RAS-MEK-ERK pathway and at the translation level by mTOR via S6K and 4EBP1. p21 and p27 
can bind to and inhibit cyclin-CDK complexes. (D) RIP-qPCR analysis showing binding of HuR to multiple genes in the RB/E2F pathway in 4 MPNST cell lines 
(ST88-14, 90-8, S462, STS-26T). Data are normalized to control IgG IPs and are presented as mean ± SEM, 2-tailed unpaired Student’s t test. (E) Representa-
tive Western blots showing a downregulation of several key RB/E2F pathway components after HuR silencing in ST88-14 MPNST cells, in general concordance 
with RIP-qPCR data. Technical duplicates are shown, and similar results were obtained in 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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ST88-14 MPNST cells (Supplemental Figure 8A), suggesting 
that HuR could be responsible for regulating expression of YAP/
TAZ pathway components.
To test this hypothesis, we examined whether HuR associated 
with mRNAs encoding key protein components of the YAP/TAZ 
pathway by performing RIP followed by reverse transcription and 
quantitative PCR analysis (RIP-qPCR) in MPNSTs. To avoid pos-
sible confounding effects of cell type heterogeneity in tumor sam-
ples, we used MPNST cell lines instead. We found that there was a 
vated HIPPO-TAZ/YAP expression, and hyperactivation of 
YAP/TAZ in Schwann cells activated an oncogenic program 
with development of MPNSTs (6). GSEA analysis of RNA-Seq 
data showed that HuR silencing in MPNST cells led to a strong 
suppression of a YAP-conserved signature (35) as well as a 
functionally validated YAP-activated signature (ref. 36 and Fig-
ure 7, A and B). Notably, GSEA also showed a strong negative 
correlation of genes regulated by YAP/TAZ hyperactivation 
in Schwann cells (6) and genes regulated by HuR silencing in 
Figure 9. HuR activates key oncogenic programs by regulating the Wnt/β-catenin pathway. (A) Compendium of normalized enrichment scores 
(NES) of target gene sets associated with the Wnt/β-catenin pathway after GSEA analysis of HuR-silenced ST88-14 MPNST cells (Supplemental 
Tables 5 and 6). Notably, there is general positive correlation in the activation of the pathways (highlighted in green) in shCtrl-infected cells. Circles 
denotes the number of enriched genes in each category, and colors represent FDR Q values. (B) GSEA plots showing enrichment of a MYC-induced 
target gene set in shCtrl cells, and a LEF1-repressed target gene set in shHuR#1-infected cells. (C) RIP-qPCR analysis showing binding of HuR to 
CTNNB1 and BCL9 in 4 MPNST cell lines (ST88-14, 90-8, S462, STS-26T). Data are normalized to control IgG IPs and are presented as mean ± SEM, 
2-tailed unpaired Student’s t test. (D) Representative Western blots showing a general downregulation of Wnt/β-catenin pathway components, 
including key oncogenic downstream regulators, after HuR silencing in ST88-14 MPNST cells. Technical duplicates are shown, and similar results 
were obtained in 3 independent experiments. (E) Representative Western blots showing that lentivirus-based expression of constitutively active 
β-catenin 4A mutant (harbors alanine substitutions at S33, S37, T41, and S45, preventing its degradation) [pcw107-β-Cat (4A)] partially blocks the 
downregulation of the key downstream regulators c-MYC, SOX9, AURKA, and AURKB by HuR silencing (shH#3) in ST88-14 MPNST cells. Technical 
duplicates are shown, and similar results were obtained in 3 independent experiments. (F) Ectopic expression of constitutively active β-catenin 
4A mutant partially blocks the effects of HuR silencing on cell numbers and ATP levels in ST88-14 MPNST cells. Data are normalized to shCtrl 
+ pcw107-EV cells and are presented as mean ± SEM. Each data point represents 1 independent experiment; 1-way ANOVA with Tukey’s multi-
ple-comparisons test. *P < 0.05; **P < 0.01; ****P < 0.001.
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To examine the specific function of HuR in controlling these 
tumorigenic pathways, we examined whether HuR was bound to 
and regulated expression of different components of these path-
ways (Figure 8C). By RIP-qPCR analysis, we found that HuR was 
bound to CCND1, CCND2, CDK2, CDK6, p27, E2F1, E2F2, and 
E2F3 mRNAs (Figure 8D). In both the ST88-14 and STS-26T cell 
lines, we found that silencing HuR strongly reduced the levels of 
several proteins encoded by these mRNAs, accordingly to the role 
of HuR in promoting mRNA stability and translation (Figure 8E 
and Supplemental Figure 9D). However, in specific cases, HuR 
can also inhibit protein translation (16), as described for p27 (37). 
Here, similarly, we found that HuR depletion led to an increase 
in p27 protein level. p21 protein levels were also increased, not 
as a direct target of HuR, but possibly as one of the key proteins 
increasing in abundance during cell senescence.
Collectively, our results suggest that HuR may play a direct 
role in driving cell cycle progression via E2F TFs in MPNST cells by 
acting at several levels: (a) by enhancing the expression of specific 
cyclins and CDKs to promote phosphorylation of RB1 to release 
E2F TFs, (b) by repressing production of p27, an inhibitor of CDKs, 
and (c) by directly regulating the levels of E2F TFs.
HuR activates a key Wnt/β-catenin oncogenic program in 
MPNSTs. Using the Sleeping Beauty forward genetic screen, 
signaling through the canonical Wnt/β-catenin pathway was 
recently identified as a key genetic driver of MPNST tumorigen-
esis (33, 34). The canonical Wnt pathway is activated after Wnt 
stimulation, leading to an inhibition in degradation of β-catenin, 
which then enters the nucleus and binds to a member of the lym-
phoid-enhancing factor 1/T cell factor (LEF1/TCF) family and 
other transcriptional cofactors including BCL9 and Pygopus to 
regulate the expression of target genes involved in diverse cellular 
processes (38). We found that HuR silencing led to a downregula-
tion of MYC, SOX9, and AURKA/B mRNAs (Supplemental Table 
4), which have previously been identified as downstream targets 
of the Wnt/β-catenin pathway in different cell systems (39–41). 
Here, we confirmed that these genes were also downstream tar-
get genes in MPNST cells by silencing β-catenin using specific 
sh RNAs in the ST88-14 and STS-26T cell lines (Supplemental Fig-
ure 10, A and B).
In line with this set of targets, GSEA analysis showed that 
several signature data sets associated with this pathway were sig-
nificantly downregulated by HuR silencing (Figure 9, A and B, 
and Supplemental Tables 5 and 6). RIP analysis showed that HuR 
associated with CTNNB1 mRNA, which encodes β-catenin as well 
as BCL9 mRNA, which we also identified as a target of HuR from 
our RIP-Chip analyses (Supplemental Table 2 and Figure 9C). A 
functional role of β-catenin in controlling MPNST cell growth and 
viability had already been shown using shRNA-mediated silencing 
of CTNNB1 (34).
HuR silencing led to a notable reduction in the levels of β-cat-
enin and BCL9 in ST88-14 (Figure 9D) and STS-26T cells (Supple-
mental Figure 10C), showing that HuR controlled protein produc-
tion from these mRNAs. HuR depletion also significantly lowered 
the levels of the key downstream targets, including c-MYC, SOX9, 
AURKA, and AURKB, further supporting a role for HuR in regu-
lating Wnt/β-catenin–mediated gene transcription. To confirm 
these results, we examined the capacity of ectopically expressing 
strong enrichment of YAP1 mRNA, encoding YAP1, and TEAD1 and 
TEAD2 mRNAs, encoding TEAD1 and TEAD2, two transcriptional 
partners of YAP1, in HuR RIP samples (Figure 7C). Notably, HuR 
depletion led to a striking reduction in the levels of these proteins in 
both the NF1-derived ST88-14 cell line (Figure 7D) and the sporadic 
cell line STS-26T (Supplemental Figure 8B). Suppressing the YAP/
TAZ pathway by HuR silencing reduced the mRNA levels of down-
stream YAP/TAZ target genes in both cell lines (Figure 7E and Sup-
plemental Figure 8C). Interestingly, although we did not find that 
TAZ or TEAD4 mRNAs were direct targets of HuR, HuR depletion 
led to a strong reduction in their expression levels, likely due to an 
indirect effect on their transcription, mRNA stability, or translation.
Our results indicate that HuR can regulate expression of key 
YAP/TAZ pathway components in MPNST cells, which could lead 
to the aberrant elevated HIPPO-TAZ/YAP expression seen in 
mouse and human tumor tissue samples and the hyperactivation 
of this essential oncogenic pathway for MPNST pathogenesis.
HuR regulates key cell cycle genes in MPNSTs via an RB/E2F axis. 
RAS/MEK/ERK and PI3K/AKT/mTOR are 2 other major signal-
ing pathways that are upregulated in MPNSTs and have important 
roles in MPNST pathogenesis (1, 2). GSEA analysis revealed that 
many components of these pathways were significantly downreg-
ulated by HuR silencing, including activation of receptor tyrosine 
kinases such as PDGF (Supplemental Figure 9, A and B). Along the 
same lines, GSEA also showed a strong positive correlation among 
genes regulated by the MEK inhibitor PD0325901 in the MPNST 
cell line 90-8TL (13) and genes regulated by HuR silencing in 
ST88-14 MPNST cells (Supplemental Figure 9C). In addition, sev-
eral signatures of downstream effectors of these pathways, includ-
ing the RB and E2F TFs, were inhibited by HuR silencing (Figure 
8, A and B). These effectors are frequently dysregulated in cancer 
and play an important role in cell cycle regulation (22).
Figure 10. HuR regulates a core transcriptional circuitry in MPNST cells. (A) 
GSEA plots showing enrichment of genes upregulated in MPNST cells by JQ1 
treatment (fold change >1.5; adjusted P value < 0.05) (13) and shHuR#1-in-
fected ST88-14 MPNST cells. (B) RIP-qPCR analysis showing binding of 
HuR to BRD2, BRD3, and BRD4 in 4 MPNST cell lines (ST88-14, 90-8, S462, 
STS-26T). Data are normalized to control IgG IPs and are presented as mean 
± SEM, 2-tailed unpaired Student’s t test. (C) Representative Western 
blots showing a downregulation of BRD proteins after HuR silencing in 
ST88-14 MPNST cells. (D) Violin plot showing the distributions of BRD2, 
BRD3, and BRD4 ChIP-Seq signal at enriched regions in shCtrl-infected and 
shHuR#1-infected ST88-14 MPNST cells. The y axis shows BRD ChIP-Seq 
signal in units of reads per million (rpm)/bp. The loss of BRD occupancy at 
BRD-enriched regions after HuR silencing is highly significant (BRD2, P = 
4.44 × 10–16; BRD3, P = 1.332 × 10–15; BRD4, P = 1.332 × 10–15; Welch’s t test). 
(E) Gene regulatory networks among differentially expressed, epigenetically 
active TFs that are either direct or indirect targets of BRD proteins. Red and 
blue circles represent differentially upregulated and downregulated TFs, 
respectively, in shCtrl-infected cells. Light green edges indicate regulatory 
interactions unique to shCtrl cells, light blue edges indicate those unique 
to shHuR#1-infected cells, and black edges indicate those present in both 
phenotypes. Pointed arrows indicate activation, and blunted arrows indicate 
inhibition. Functional categories are based on Gene Ontology Biological Pro-
cesses. (F) GSEA plot showing strong enrichment of epigenetically active TFs 
that are either direct or indirect targets of BRD proteins in shCtrl-infected 
compared with shHuR#1-infected ST88-14 MPNST cells. (G and H) ToppGene 
analysis of HuR-regulated TF network in MPNSTs (red circles from E), as 
classified according to pathway categories (G) or disease (H).
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Key recent studies have shown that JQ1 treatment in melano-
ma and multiple myeloma cells depletes BRD2 and BRD4 from 
promoter and enhancer regions of the genome, and this was asso-
ciated with the disruption of transcriptional programs in these 
cells (43, 44). To gain mechanistic insight into the role of HuR in 
mediating the function of BET proteins in MPNST cells, we inves-
tigated changes in BET occupancy on a genome scale by ChIP-Seq 
in ST88-14 cells after HuR silencing. We found that HuR silenc-
ing significantly reduced genome-wide BRD2, BRD3, and BRD4 
occupancy by approximately 60%, approximately 50%, and 
approximately 45%, respectively (Figure 10D).
Next, to examine the functional effects of the BETs’ occupancy 
on transcriptional regulation, we generated a chromatin landscape 
in ST88-14 cells using H3K4me3 to identify promoters, H3K4me1 
to identify enhancers, and H3K27ac to identify active promoter/
enhancer regions. Using this information, we performed network 
analysis to generate a network of transcriptional regulators that 
are targets of BRD proteins and regulated by HuR expression. In 
brief, we identified BRD-bound epigenetically active (active pro-
moters and enhancers) and differentially regulated TFs in control 
and HuR-silenced cells (Figure 10E). It is apparent from this anal-
ysis that there is a considerable number of transcriptional regu-
lators in MPNST cells that are associated with BRD proteins and 
that control key processes, such as proliferation. Importantly, we 
found that a substantial proportion of these transcriptional regu-
lators were especially sensitive to HuR inhibition, which depleted 
BRD proteins from their promoter/enhancer regions and down-
regulated their expression (Figure 10E, red circles). Thus, GSEA 
analysis of BRD-bound transcriptional regulators demonstrated 
a significant enrichment of genes activated in control cells and 
repressed by HuR silencing (Figure 10F). Gene enrichment anal-
ysis by ToppGene suite (45) identified these repressed regulators 
as being overrepresented in different oncogenic pathways, includ-
ing E2F and MYC TF networks, proliferation, and TP53-regulated 
pathways, and for different cancers (Figure 10, G and H).
Collectively, these data demonstrate that BRD proteins are 
enriched at promoter/enhancer regions of key transcriptional reg-
ulators in MPNST cells, and that a reduction in their levels and 
genome occupancy by HuR silencing suppresses this oncogenic 
transcriptional circuitry.
Discussion
Cancer arises from multiple genetic lesions that lead to aberrant 
gene expression programs, which are increasingly being recog-
nized as fundamental for the acquisition, development, and main-
tenance of cancer phenotypes. Compelling recent evidence shows 
that cancer cells can develop absolute dependencies on discrete 
molecular regulators — out of the thousands of human proteins 
that contribute to control of gene expression — that drive these 
dysregulated transcriptional programs. There is nowadays an 
intense search for these key regulators through focused mechanis-
tic studies, since they represent attractive targets for effective and 
enduring therapies in cancer (9, 10).
In this study, we present evidence that MPNST cells exhibit 
an exceptional reliance on the RNA-binding protein HuR for their 
abilities to survive, proliferate, and disseminate. HuR inhibition 
prevented the formation of tumors in xenograft models, and even 
a degradation-resistant form of β-catenin to abrogate the effects 
of HuR silencing in MPNST cells. We found that constitutive 
expression of the β-catenin mutant partially blocked the effects 
of HuR silencing on downregulation of the downstream Wnt path-
way targets in ST88-14 MPNST cells (Figure 9E). In line with this, 
although silencing HuR still reduced ATP levels and cell number 
in cells overexpressing the β-catenin mutant, there was a signif-
icant recovery of these parameters in comparison with HuR-si-
lenced cells expressing the empty vector plasmid (Figure 9F). Sim-
ilar results were obtained in the sporadic MPNST STS-26T cell line 
(Supplemental Figure 10, D and E).
Conversely, overexpression of BCL9 using a lentiviral vec-
tor failed to rescue the suppression of MPNST growth induced 
by HuR silencing (data not shown), suggesting that regulation of 
BCL9 is not central to the biological consequences elicited by HuR 
in MPNST cells. Our results above also show that a number of key 
oncogenic TFs, including c-MYC, SOX9, or E2Fs, were downregu-
lated by HuR silencing. Similarly, here, we found no major effect 
on MPNST growth when the expression of these TFs was restored 
using lentiviral overexpression constructs after HuR silencing 
(Supplemental Figures 11 and 12).
These data suggest that there is hierarchical prioritization for 
HuR function in MPNSTs: HuR primarily regulates the expression 
of key master regulators (e.g., β-catenin, YAP/TAZ), which in turn 
control the production of cell cycle proteins and TFs.
HuR regulates a core transcriptional circuitry in MPNST cells by 
controlling expression of BRD proteins. Deregulation of the epig-
enome has also emerged as an important component of the patho-
genesis of MPNSTs. In particular, 2 recent studies pointed to a 
role of bromodomain and extraterminal domain (BET) proteins 
in the activation and maintenance of an aberrant transcriptional 
program (13, 32). BET proteins, including bromodomain-contain-
ing protein 2 (BRD2), BRD3, and BRD4, bind to hyperacetylated 
lysines in promoter/enhancer regions, and subsequently recruit 
cofactors to control transcription of oncogenic drivers, such as 
MYC and E2F (42).
In MPNST cells, a small-molecule inhibitor of the BET pro-
teins, JQ1, blocks proliferation and can induce apoptosis in MPNST 
cells in vitro and in vivo, highlighting the importance of these pro-
teins in MPNST pathogenesis (13, 32). Using GSEA analysis, we 
found a striking enrichment of genes activated by JQ1 treatment in 
MPNST cells (13), and genes upregulated by HuR silencing in our 
data set (Figure 10A). Furthermore, in line with our RIP-Chip anal-
yses, where we found enrichment of BRD2 mRNA in HuR-bound 
fractions (Supplemental Table 2), we found that mRNAs encoding 
all 3 BET family members, BRD2, BRD3, and BRD4, were highly 
enriched in HuR fractions in RIP-qPCR analyses of MPNST cell 
lines (Figure 10B). HuR silencing strongly reduced all 3 BET pro-
teins in both the ST88-14 and STS-26T cell lines, suggesting a role 
for HuR in promoting the stability and/or translation of the cor-
responding mRNAs (Figure 10C and Supplemental Figure 13A). 
A functional role of BRD4 in controlling cell growth and viability 
in MPNST cells had already been shown using shRNA-mediated 
silencing (13, 32). Here, we found that silencing BRD2 using 2 dis-
tinct BRD2-specific shRNAs also led to a reduction in cell growth 
and viability (Supplemental Figure 13, B–D), underscoring the 
importance of this transcriptional regulator in MPNSTs.
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the drugs. This paradigm is also consistent with the disappointing-
ly poor results obtained in phase I and II clinical trials targeting 
individual components of kinase cascades in MPNST patients. 
Because of the superior results obtained from additive effects of 
cotargeting multiple pathways, current clinical trials are more 
focused on combination drug therapy (1, 25). Our results strong-
ly argue that targeting HuR could be equally as effective as the 
combined treatments, as we find that HuR inhibition potently 
suppresses several of the oncogenic signals in MPNSTs, leading to 
profound cytostatic and cytotoxic effects on the growth, as well as 
the metastatic capacity, of tumors.
Strikingly, we find that targeting HuR can both prevent the 
formation of tumors and metastatic nodules, and lead to shrink-
age of fully established tumors and metastases. Thus, therapeu-
tic intervention could be equally effective in newly diagnosed or 
recurrent tumors, which has particularly appealing translational 
importance, since timing of intervention and stage of disease have 
been raised as possible causes of the negative results in clinical 
trials in MPNSTs. However, even though our promising data on 
pharmacological inhibition of HuR could represent a viable thera-
py for patients with MPNSTs, it is still unclear whether the preclin-
ical efficacy observed in this study using cell lines and mice can be 
translated to the clinic. Whether HuR is a valid therapeutic target 
in MPNSTs warrants direct investigation.
Our ChIP-Seq data reveal a large network of transcriptional 
regulators operating in MPNST cells that are associated with key 
biological functions. Notably, we find that this network is highly 
sensitive to levels of HuR, which can regulate expression of key 
components of this network via modulation of BRD protein levels 
and/or signaling pathways. An essential role for BRD proteins in 
regulating gene expression has also been shown in several malig-
nancies, including MPNSTs, and interestingly, we find that HuR 
silencing in MPNSTs phenocopies to a large extent treatment 
with the BET inhibitor JQ1, at least in terms of gene expression 
profiles. In addition, the displacement of BRD proteins on pro-
moter/enhancer regions of active cancer-related genes by JQ1 in 
hematological malignancies and melanoma (42–44) is similar to 
the reduced promoter/enhancer occupancy on transcriptional reg-
ulators in MPNSTs that we found after HuR silencing. Thus, our 
data suggest that dysregulation of the transcriptional program in 
MPNSTs by HuR silencing could be in large part mediated by the 
influence of HuR on the MPNST transcriptional network.
Remarkably, we found that HuR depletion led to strong sup-
pression of MYC and E2F levels that was accompanied by a high-
ly significant reduction in the abundance of MYC- and E2F-tran-
scribed gene sets, pointing to a general suppression of transcription 
at E2F- and MYC-driven targets by HuR inhibition. These proto- 
oncogenic TFs are among the most important drivers of tumori-
genesis, as they regulate cell growth, proliferation, apoptosis, and 
metabolic pathways (22, 23), and represent some of the important 
targets for cancer therapy, although efforts to directly target these 
TFs have proved unsuccessful so far (9). Our work could thus have 
far-reaching implications for cancer therapy, since it suggests an 
alternative strategy to effectively target these TFs. MYC regulation 
also represents one of the best examples of the “multifunctional” 
capacity of HuR in driving expression of particular oncoproteins. 
MYC levels are regulated by major growth-regulatory and onco-
induced a striking regression of tumor volume in established 
tumors. Furthermore, HuR strongly promoted the metastatic 
capacity of MPNST cells, one of the worst prognostic features of 
this cancer. We propose that HuR-regulated transcriptomes pro-
mote the survival and adaptation strategies that allow the dis-
seminated cancer cells to survive in the circulation and migrate 
to, extravasate, and thrive in incompatible foreign microenviron-
ments of distant tissues. Consistent with these results, we found 
that HuR regulated essential biological capabilities of MPNST 
cells, including cell cycle progression and sustained prolifera-
tion, resisting cell death in stress conditions and enabling repli-
cative immortality. Notably, the functional consequences of HuR 
inhibition were largely comparable in a representative panel of 4 
MPNST cell lines obtained from patients with different NF1 sta-
tus, even though these exhibit heterogeneous cellular growth rates 
and alterations in expression of a number of cell cycle proteins 
(24). This lack of major differences, functional or mechanistic, 
between NF1-derived and sporadic MPNSTs after HuR silencing 
supports the view that relatively similar molecular mechanisms 
are involved in the pathogenesis of MPNSTs, and that HuR can be 
a broad target for MPNSTs, irrespective of NF1 status (1).
Mechanistically, our RIP-Chip and transcriptomics data 
showed a global dysregulation of several signaling pathways and 
molecular regulators in these cancer cells, including the HIP-
PO-YAP/TAZ, PI3K/AKT/mTOR, RAS/RAF-MEK-ERK, and Wnt/ 
β-catenin pathways and bromodomain regulation of gene tran-
scription, while our focused analyses revealed that regulation 
by HuR of specific components of these pathways likely led to 
the aberrant signaling. Several of these pathways, including 
Wnt/β-catenin, seem to be specific to MPNSTs, since we find 
that HuR cannot regulate them in normal Schwann cells (data 
not shown). We posit that this capacity of HuR to simultaneous-
ly control several essential molecular regulators that operate 
in these cancer cells explains in large part the striking effects of 
HuR inhibition in MPNST cells. All these pathways have been 
shown to contribute to MPNST pathogenesis in seminal studies 
from several laboratories using various genetically engineered 
mouse models or culture systems (1, 2, 6, 13, 32–34, 46). However, 
genetic or pharmacological inhibition of these targets individual-
ly has, in general, been modestly effective and largely cytostatic. 
Instead, concurrent targeting of different pathways has proved 
more potent. Thus, combined inhibition of YAP/TAZ and PDGFR 
signaling activity (6), BRD proteins and MEK activity (13), or the 
mTOR and Wnt/β-catenin pathways (34) is strongly synergistic in 
blocking tumor growth, and can even induce apoptosis.
These observations strongly support the view that parallel and 
redundant pathways control the oncogenic traits in MPNST cells, 
a phenomenon that has been associated with the emergence of 
therapeutic resistance in cancer cells (10, 21). This is particular-
ly true for targeted therapies against kinase-mediated signaling 
cascades, which are organized in a linear and hierarchical man-
ner, with different receptor tyrosine kinases at the top, activating 
a reduced number of kinase signaling cascades, including RAS/
RAF-ERK, PI3K/AKT, and JAK/STAT, that operate in parallel but 
that can crosstalk with one another (10). This linear and redun-
dant architecture facilitates bypassing of a signaling pathway after 
its inhibition for another, thus blocking the therapeutic effects of 
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tericin (Gibco). Fascicles were then digested in DMEM with 10% FBS, 
500 U/mL penicillin/streptomycin, 0.8 U/mL dispase grade I (Milli-
poreSigma), and collagenase type 1A 160 U/mL (MilliporeSigma). 
The resulting Schwann cells were then amplified on plates coated with 
0.1 mg/mL poly-l-lysine in DMEM with 20% FBS, 100 U/mL peni-
cillin/streptomycin, 0.5 mM forskolin (MilliporeSigma), 2.5 mg/mL 
amphotericin, 2.5 mg/mL insulin (MilliporeSigma), 10 nM β1-hereg-
ulin (MilliporeSigma), and 0.5 mM IBMX (MilliporeSigma). Amplified 
Schwann cells were plated in DMEM with 10% FBS in the absence of 
β1-heregulin for at least 24 hours before analysis.
Lentivirus preparation and infection of MPNST cells. Lentiviral par-
ticles (Supplemental Table 7) were produced in HEK293FT cells. For 
single-infection experiments, MPNST cells were incubated with dif-
ferent lentiviral particles together with 8 μg/mL Polybrene (Merck) for 
enhancing infection efficiency. Selection of infected cells was started 
48 hours after infection with puromycin (4 μg/mL) for 2 days in sup-
plemented growth medium or with geneticin (G418 sulfate) (Thermo 
Fisher Scientific) at 50 μg/mL for 5 days in growth medium without 
antibiotic/antimycotic. For the inducible knockdown plasmids, after 
infection and selection, cell lines were treated with 0.5 μg/mL dox-
ycycline every 24 hours for 3 days. Infection efficacy was tested by 
Western blot and quantitative reverse transcriptase PCR analyses. For 
rescue experiments, cells were first infected with control or β-catenin–
overexpressing plasmids and selected with puromycin, and then fur-
ther infected with shHuR#3 lentiviral particles followed by selection 
with geneticin, as above. After infection and selection, MPNST cells 
were replated at specific densities for the different functional assays. 
All assays were conducted in triplicate, with at least 3 independent 
experiments performed for each assay.
Small-molecule HuR inhibitors. For culture studies, MPNST cell 
lines were treated with the following small-molecule HuR inhibitors 
for 48 hours: (a) MS-444 (29), obtained from Philipp Krastel (Novar-
tis Institutes for Biomedical Research), reconstituted in DMSO and 
used at a final concentration of 10 μM; (b) pyrvinium pamoate (Milli-
poreSigma), reconstituted in DMSO and used at a final concentration 
of 2 μM; and (c) tanshinone mimic 6N (TM-6N) (31), obtained from 
Alessandro Provenzani (University of Trento), reconstituted in DMSO 
and used at a final concentration of 10 μM. 0.1% DMSO was used in 
control cultures.
For in vivo xenograft studies, 1 × 106 STS-26T cells mixed in 1:4 
PBS/Matrigel were injected subcutaneously in the left and right back 
flanks of mice, respectively, under standard procedures and tumors 
allowed to grow up to 100 mm3 average volume, as described above. 
The mice then received i.p. injections of MS-444 (25 mg/kg) dissolved 
in PBS/5% N-methyl pyrrolidine (NMP) (MilliporeSigma) or vehicle 
control every 48 hours for a further 10 days.
For lung metastasis studies, 1 × 106 STS-26T cells were injected in 
the lateral tail vein of mice and left for 2 weeks to allow basal forma-
tion of lung metastases, as described above. The mice then received 
i.p. injections of MS-444 (25 mg/kg) dissolved in PBS/5% NMP (Mil-
liporeSigma) or vehicle control every 48 hours for a further 2 weeks.
All the microarray, RNA-Seq, and ChIP-Seq data were deposited 
in the NCBI Gene Expression Omnibus database (GEO GSE120687).
Statistics. All analyses were done using Microsoft Excel or 
GraphPad Prism 6.00 (www.graphpad.com). Data are shown in dot 
plots or histograms as mean ± SEM. A P value of less than 0.05 is 
deemed statistically significant. Statistical analysis was performed 
genic signaling pathways, including the Wnt/β-catenin, JAK/STAT, 
and Notch pathways that induce MYC transcription and the mTOR 
pathway that increases the efficiency of MYC mRNA translation, 
together with function of PI3K and RAS signaling and AURKA/B 
that increase the stability of MYC protein (22, 47). The striking 
downregulation of MYC levels in MPNST cells by HuR inhibition 
could potentially be mediated by a combinatorial action at several 
of these nodes of regulation, which are themselves under strong 
HuR influence. Similarly, E2F levels/function in MPNST cells 
could be determined by HuR via its effect on multiple regulatory 
mechanisms, including cyclin-CDK expression, RB phosphoryla-
tion, and E2F transcription/translation.
RBPs play a central role in regulation of gene expression, and 
thus it is not surprising that their dysregulation has been linked 
to several human diseases, including neurological disorders and 
cancer (48, 49). These dynamic regulators can bind to and reg-
ulate thousands of functionally related genes, regulating every 
hallmark of cancer cells. Recent detailed studies have shown that 
RBPs are rapidly emerging as key oncogenic drivers in a variety of 
malignancies (48, 50–53). In this study, we show that the RBP HuR 
has pleiotropic functions in MPNSTs, driving tumor growth and 
metastasis by, quite strikingly, influencing almost all key signaling 
pathways and regulators discovered in MPNSTs so far, including 
the PI3K/AKT/mTOR, RAS/RAF-MEK-ERK, Wnt/β-catenin, and 
HIPPO-YAP/TAZ pathways, and transcriptional regulators includ-
ing SOX9, AURKA/B, and BRD proteins, as well as the proto-on-
cogenic TFs MYC and E2Fs. Over 1500 RBPs have been described, 
and several of them are dysregulated in MPNSTs (data not shown). 
It would be interesting to examine their biological and mechanis-
tic functions in MPNSTs, and whether they have broad functions 
similar to those of HuR or regulate distinct pathways.
This function of HuR in establishing the highly intricate reg-
ulatory networks operating in MPNSTs to coordinate multiple 
cancer hallmark traits supports a “master” regulatory function 
for HuR in MPNSTs. Thus, by elevating HuR levels, MPNST cells 
have elaborated an adaptive mechanism to amplify and regulate 
key oncogenic signals and modulate transcriptional programs to 
confer a competitive advantage to these cancer cells, promoting 
MPNST growth and metastatic spread (see Graphical Abstract).
Methods
Cell culture. Human MPNST cell lines S462, STS-26T, ST88-14, and 
90-8 and an immortalized normal human Schwann cell line (iHSCλ2) 
were obtained from Nancy Ratner (Cincinnati Children’s Hospital Med-
ical Center) (24, 34). Immortalized plexiform neurofibroma–derived 
Schwann cells (ipNF SC) were purchased from ATCC (ATCC CRL 
3390). The cells were maintained in DMEM (Thermo Fisher Scientific) 
supplemented with 10% (vol/vol) FBS (Thermo Fisher Scientific) and 
1% (vol/vol) antibiotic/antimycotic (Thermo Fisher Scientific) under 
standard conditions of culture in 37°C and 5% CO2.
Human Schwann cells were isolated from the sural nerves of 
donors with informed consent (see below). Withdrawn nerves were 
stripped of their epineurium, and fascicles were separated from 
the remaining interfascicular epineurium. Fascicles were cut into 
2-mm-long pieces and incubated in humidified conditions and 10% 
CO2 for 7–14 days in DMEM (Gibco) with 10% FBS (MilliporeSigma), 
500 U/mL penicillin/streptomycin (Gibco), and 2.5 mg/mL ampho-
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